Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion

Madrigal Pharmaceuticals (NASDAQ:MDGL) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 22, MDGL announced a $500 million senior secured credit facility with Blue Owl Capital Inc. (NYSE:OWL), including a $350 million initial term loan and a $150 million delayed draw option through 2027.

The non-dilutive funding will refinance $115 million in existing debt and support strategic growth, with potential for an additional $250 million. Madrigal maintains a strong current ratio of 5.91, signaling solid liquidity.

The capital will primarily advance Madrigal’s pipeline for metabolic dysfunction-associated steatohepatitis (MASH), led by its FDA-approved drug Rezdiffra—the first treatment for MASH with moderate to advanced fibrosis. A Phase 3 trial is underway to evaluate Rezdiffra for compensated MASH cirrhosis. With strong launch momentum and a patent expected to extend protection through 2044, Madrigal is positioned to lead in MASH therapeutics.

Madrigal Pharmaceuticals (NASDAQ:MDGL) is a biotech company that develops and commercializes novel therapies for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH).

While we acknowledge the potential of MDGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.